The American journal of tropical medicine and hygiene · 2024
Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Date Kashmira, LeBoa Christopher, Hoffman Seth A, Haldar Pradeep, Harvey Pauline, An Qian, Zhang Chenhua, Yewale Vijay N, Daruwalla Savita, Dharmapalan Dhanya, Gavhane Jeetendra, Joshi Shrikrishna, Rai Rajesh, Rathod Varsha, Shetty Keertana, Warrier Divyalatha S, Yadav Shalini, Shimpi Rahul, Jayaprasad Niniya, Horng Lily, Fagerli Kirsten, Borhade Priyanka, Chakraborty Debjit, Katkar Arun, Kunwar Abhishek, Andrews Jason R, Bahl Sunil, Bhatnagar Pankaj, Dutta Shanta, Luby Stephen P
Аннотация
Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05-0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0-95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.